Generation Z was the most likely to say they would be willing to share their tracked data from their mobile devices and wearables with their providers, and the most likely to choose a provider based on their use of personalized medicine.
SAN FRANCISCO (PRWEB) April 30, 2019
Dosis, an AI-powered personalized dosing platform, and the developer of the Strategic Anemia Advisor (SAA) decision support tool, today released findings from the 2019 Dosis Personalized and Digital Medicine Consumer Report. The report surveyed more than 1,000 consumers, weighted for the U.S. population, to gain a better understanding of how big the disconnect is between the advances in personalized medicine approaches and general consumer awareness of its benefits.
While the report found awareness of personalized medicine has risen to 33% in 2019, the progress with educating patients on the improvements in care that it can bring, along with the treatments associated with its practice, continues to be slow. In fact, consumer awareness has only grown by around 1% year-over-year since 2013.
Highlights from the 2019 Dosis Personalized and Digital Medicine Consumer Report include:
- Consumer awareness of personalized medicine has risen to 33% from 29% in 2018
- 24% of consumers would take a diagnostic test referred by their healthcare provider to gain access to personalized medicine
- Generation Z (18-24-year-olds) were the most likely (17%) to say they would be willing to share their tracked data from their mobile devices and wearables with their providers, and the most likely (26%) to choose a provider based on their use of personalized medicine
- 6% of U.S. consumers say they have used an at-home DNA or genetic test with the goal of sharing with their provider to inform their treatment plan
- 32% of consumers would go outside of their insurance coverage for personalized medicine options if confronted with a potentially serious condition
- 37% of consumers, and 43% of those 55+, say their prescription or medication dosages aren’t optimal or personalized enough
“As more consumers are educated on how their genetic makeup, lifestyle and environmental factors uniquely affect their medical treatments, I believe both awareness of and interest in personalized medicine will continue to grow,” said Shivrat Chhabra, Founder & CEO of Dosis. “Younger patients have expressed growing dissatisfaction with traditional care, and the findings of our report indicate that their interest in technology may be a major opportunity to further their awareness in personalized medicine alternatives.”
The full report is available here.
Dosis, an AI-powered personalized dosing platform, is the developer of the Strategic Anemia Advisor (SAA) clinical decision support tool. SAA is currently revolutionizing anemia management for more than 5,000 dialysis patients at more than 50 dialysis clinics across the country by supporting healthcare providers with determining a patient’s unique response to erythropoietin-stimulating agents (ESA) and recommending personalized dosages that keep individual patients within their hemoglobin target ranges. Dosis is headquartered in San Francisco. For more information, visit dosisinc.com.